Compare BBAR & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BBAR | TLX |
|---|---|---|
| Founded | 1886 | 2015 |
| Country | Argentina | Australia |
| Employees | N/A | 1184 |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.6B |
| IPO Year | 1997 | N/A |
| Metric | BBAR | TLX |
|---|---|---|
| Price | $21.28 | $11.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $17.00 | ★ $21.13 |
| AVG Volume (30 Days) | ★ 714.8K | 212.0K |
| Earning Date | 05-20-2026 | 08-19-2026 |
| Dividend Yield | ★ 2.04% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.32 | N/A |
| Revenue Next Year | $11.04 | N/A |
| P/E Ratio | ★ $26.78 | $150.33 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.76 | $6.28 |
| 52 Week High | $22.47 | $16.85 |
| Indicator | BBAR | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 61.75 | 55.49 |
| Support Level | $17.03 | $9.46 |
| Resistance Level | $21.92 | $11.38 |
| Average True Range (ATR) | 1.13 | 0.28 |
| MACD | -0.09 | 0.06 |
| Stochastic Oscillator | 71.69 | 52.96 |
Banco BBVA Argentina SA is a banking services provider in Argentina. It provides financial assistance to large corporations, small and medium-sized companies, as well as individuals. It bank provides services through retail, corporate, investment banking, and Small and medium-sized companies divisions. Through the retail banking segment, it provides banking products and services to individuals, corporate banking deals with services to corporates, and the small and medium-sized companies segment focuses on foreign trade, agricultural business, and digital products.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.